Addition of pTau217 test further expands the company's leadership in testing options for Alzheimer's disease to improve patient care

pTau217测试的加入进一步扩大了该公司在阿尔茨海默病测试选项方面的领导地位，以改善患者护理

BURLINGTON, N.C., March 20, 2024 /PRNewswire/ -- LabCorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch and immediate availability of its test to identify the presence or absence of phosphorylated tau 217 (pTau217), a pivotal blood biomarker designed to aid in the diagnosis of Alzheimer's disease and the subsequent monitoring of patients undergoing treatment with new Alzheimer's disease therapies.

北卡罗来纳州伯灵顿，2024年3月20日，创新和综合实验室服务的全球领导者LabCorp（纽约证交所：LH）今天宣布推出并立即提供其测试，以确定磷酸化tau 217（pTau217）的存在与否，这是一种关键的血液生物标志物，旨在帮助诊断阿尔茨海默氏病，并随后监测接受新阿尔茨海默氏病疗法治疗的患者。

Labcorp's pTau217 test can be ordered by physicians and used in clinical trials and research by global biopharmaceutical partners..

Labcorp的pTau217测试可以由医生订购，并由全球生物制药合作伙伴用于临床试验和研究。。

Alzheimer's disease, the most prevalent form of dementia, poses a significant health challenge globally. An estimated 6.7 million Americans are currently living with Alzheimer's disease, a figure projected to more than double to 13.8 million individuals by 2060. The pTau217 marker has been used in Alzheimer's drug trials to monitor patients on anti-amyloid therapy..

阿尔茨海默病（Alzheimer's disease）是最普遍的痴呆症，在全球范围内构成了重大的健康挑战。据估计，目前有670万美国人患有阿尔茨海默氏病，预计到2060年，这一数字将增加一倍以上，达到1380万人。pTau217标记物已用于阿尔茨海默病药物试验，以监测抗淀粉样蛋白治疗患者。。

Labcorp's introduction of pTau217 as a standalone test marks a significant advancement in the company's Alzheimer's testing portfolio, complementing its existing array of blood-based biomarker testing, including:

Labcorp推出pTau217作为独立测试标志着该公司阿尔茨海默氏病测试组合的重大进步，补充了其现有的一系列基于血液的生物标志物测试，包括：

Beta amyloid 42/40 ratio, which provides an indication of amyloid pathology for Alzheimer's disease and is available nationwide for clinicians and available in Europe as a CE-marked assay.

β-淀粉样蛋白42/40比率，它提供了阿尔茨海默病淀粉样蛋白病理学的指示，可在全国范围内供临床医生使用，并可在欧洲作为CE标记的检测方法获得。

Neurofilament light chain (NfL), which provides an indication of disease severity by measuring current levels of neurodegeneration.

神经丝轻链（NfL），通过测量当前的神经变性水平来指示疾病的严重程度。

ATN Profile, which combines three blood biomarkers – beta amyloid 42/40, NfL and pTau181. The ATN Profile provides physicians with an accessible and interpretable blood test to assess pathologies associated with Alzheimer's disease and other neurodegenerative conditions, which can help accelerate the path to diagnosis and intervention..

ATN概况，它结合了三种血液生物标志物-β淀粉样蛋白42/40，NfL和pTau181。ATN概况为医生提供了一种可访问且可解释的血液测试，以评估与阿尔茨海默氏病和其他神经退行性疾病相关的病理，这可以帮助加速诊断和干预的途径。。

'The introduction of pTau217 represents a significant milestone in our ongoing commitment to advancing testing capabilities across the spectrum of Alzheimer's disease,' said Dr. Brian Caveney, Labcorp's Chief Medical and Scientific Officer. 'By expanding our suite of blood-based biomarker tests, we are empowering clinicians and pharma with more tools for clinical trials and for the detection and monitoring of Alzheimer's to improve patient care.'.

Labcorp首席医学和科学官布赖恩·卡文尼（BrianCaveney）博士说，pTau217的推出标志着我们持续致力于提高阿尔茨海默病检测能力的一个重要里程碑通过扩展我们的一套基于血液的生物标志物测试，我们正在为临床医生和制药公司提供更多的临床试验工具，以及用于检测和监测阿尔茨海默氏病的工具，以改善患者护理。”。

For more information about the pTau217 biomarker and the use of Labcorp's new test in patient care, visit http://www.labcorp.com/alzheimers.

有关pTau217生物标志物以及Labcorp新测试在患者护理中的应用的更多信息，请访问http://www.labcorp.com/alzheimers.

For biopharma laboratory services inquiries, please visit https://www.labcorp.com/neurology/neurodegenerative-diseases/pharmaceutical-partners.

有关生物制药实验室服务的查询，请访问https://www.labcorp.com/neurology/neurodegenerative-diseases/pharmaceutical-partners.

About Labcorp

关于Labcorp

Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities.

Labcorp（纽约证券交易所代码：LH）是创新和综合实验室服务的全球领导者，可帮助医生、医院、制药公司、研究人员和患者做出明确而自信的决定。我们通过无与伦比的诊断和药物开发实验室能力，为改善健康和改善生活提供见解和先进科学。

The company's more than 67,000 employees serve clients in over 100 countries, worked on over 84% of the new drugs approved by the FDA in 2023 and performed more than 600 million tests for patients around the world. Learn more about us at www.labcorp.com..

该公司拥有67000多名员工，为100多个国家的客户提供服务，2023年FDA批准的新药中有84%以上是由该公司研发的，并为全球患者进行了6亿多次检测。有关我们的更多信息，请访问www.labcorp.com。。

View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-launches-ptau217-blood-biomarker-test-to-accelerate-path-to-diagnosis-of-alzheimers-disease-and-support-clinical-trials-302094433.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/labcorp-launches-ptau217-blood-biomarker-test-to-accelerate-path-to-diagnosis-of-alzheimers-disease-and-support-clinical-trials-302094433.html

SOURCE Labcorp

来源：LabCorp

Company Codes: NYSE:LH

公司代码：纽约证券交易所：LH